Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 8/20 | 0.58 |
| ▸ | JAK2 | O60674 | 6/20 | 0.58 |
| ▸ | TYK2 | P29597 | 5/20 | 0.58 |
| ▸ | JAK3 | P52333 | 5/20 | 0.58 |
| ▸ | STAT3 | P40763 | 2/20 | 0.58 |
| ▸ | KDR | P35968 | 2/20 | 0.51 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.51 |
| ▸ | ABL1 | P00519 | 1/20 | 0.51 |
| ▸ | GSK3B | P49841 | 1/20 | 0.51 |
| ▸ | AURKA | O14965 | 1/20 | 0.49 |
| ▸ | IGF1R | P08069 | 4/20 | 0.47 |
| ▸ | CDK19 | Q9BWU1 | 2/20 | 0.46 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.46 |
| ▸ | AXL | P30530 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22545979 | 1.00 | JAK1 (0.58) | JAK1JAK2TYK2JAK3STAT3 | |
| SCHEMBL4561135 | 0.90 | JAK1 (0.60) | JAK1JAK2TYK2JAK3STAT3 | |
| SCHEMBL4560821 | 0.88 | AXL (0.59) | JAK1JAK2TYK2JAK3STAT3 | |
| SCHEMBL5022297 | 0.88 | JAK1 (0.61) | JAK1JAK2TYK2JAK3STAT3 | |
| SCHEMBL4561983 | 0.88 | JAK2 (0.58) | JAK1JAK2TYK2JAK3STAT3 | |
| SCHEMBL4561905 | 0.87 | JAK2 (0.64) | JAK1JAK2TYK2JAK3STAT3 | |
| SCHEMBL22544660 | 0.86 | CDK19 (0.57) | JAK1JAK2TYK2JAK3KDR | |
| SCHEMBL29754198 | 0.86 | CDK19 (0.57) | JAK1JAK2TYK2JAK3KDR | |
| SCHEMBL4559669 | 0.86 | JAK1 (0.59) | JAK1JAK2TYK2JAK3STAT3 | |
| SCHEMBL22097741 | 0.86 | JAK2 (0.54) | JAK1JAK2TYK2JAK3STAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220259182-A1 | BENZETHERS AND ANILINES OF PYRAZOLYL-AMINO-PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2022-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220259182-A1 | BENZETHERS AND ANILINES OF PYRAZOLYL-AMINO-PYRIMIDINYL DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | JAK3, JAK1, JAK2 | JAK1 2/4885JAK2 3/4885TYK2 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.